We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKanabo Grp Plc Regulatory News (KNB)

Share Price Information for Kanabo Grp Plc (KNB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.70
Bid: 1.50
Ask: 1.90
Change: 0.00 (0.00%)
Spread: 0.40 (26.667%)
Open: 1.70
High: 1.70
Low: 1.70
Prev. Close: 1.70
KNB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Extension

9 Jun 2022 07:00

RNS Number : 2925O
Kanabo Group PLC
09 June 2022
 

 

Kanabo Group Plc.

("Kanabo" or the "Company")

 

Contract Extension

 

The GP Service Extends its Contact with a Major UK Food Retailer

 

Kanabo Group Plc. (LON: KNB), announces an extension to its existing contract between the GP Service and one of the United Kingdom's ("UK") largest group of retail businesses including food retail, wholesale, e-pharmacy, insurance, and legal services.

 

The recently acquired GP Service, originally partnered with the retailer in 2019, for the provision of general medical assistance for its members. The original agreement was limited to the submission of the patient's medical history online where the GP Service doctors would review information provided by the patient and complete the prescription for the retailer to arrange subsequent fulfilment and delivery of any approved medication.

 

Under the new Contract Extension, the GP Service will also now provide live Video Consultation services with prescriptions available for collection through the GP Service partner network of over 4,000 pharmacies across the UK. Users will normally see a doctor and may receive a prescription for collection on the same video call. In addition to prescription services, the GP Service will also provide fit notes and referrals.

 

Consultations will be available between 8am and 8pm, Monday to Sunday, 365 days a year. Consultations are usually available within 30 minutes with approximately 95% of all prescriptions available within 60 minutes of the consultation.

 

Atul Devani, CEO of the GP Service commented: "The extension of this agreement reflects the successful relationship we have had since we began working together in 2019. Our integration with the NHS summary care records ensures our services are both safe & secure and we now look forward to extending our services to include virtual GP consultations with automated digital prescriptions."

 

Kanabo, CEO, Avihu Tamir, said: "I am delighted to see this contract extension with a major retailer in the UK, which goes a long way to validating our rationale for the acquisition earlier this year. The GP Service is an innovative Telemedicine Provider, that forms an integral part of the overall strategy at Kanabo, and I look forward to extending our services in the UK further over the coming months and years."

 

 

For further information, please visit http://www.kanabogroup.com/ or https://www.voxmarkets.co.uk/listings/LON/KNB or contact the following:

 

Kanabo Group Plc

Via Vox Markets

Avihu Tamir, CEO

Peterhouse Capital Ltd (Financial Adviser)

Tel: +44 (0)20 7469 0930

Eran Zucker / Lauren Riley

Vox Markets (Investor Relations)

KanaboGroup@voxmarkets.co.uk

Kat Perez

kperez@voxmarkets.co.uk

 

 

 

About Kanabo Group Plc

Kanabo Group Plc is creating a new standard in the medical cannabis industry to improve the well-being of millions of people around the world by providing a better alternative to the smoking of medicinal cannabis flowers. Kanabo, which was the first medicinal cannabis company to IPO on London Stock Exchange, has a focus on the distribution of cannabis-derived products for medical patients and non-THC products for CBD consumers.

 

It has conducted extensive Research & Development to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions. Kanabo sells a range of medical cannabis products and wellness CBD products in the Primary Markets, including its VapePod, which delivers a metered dose with every inhalation.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFIFEERDIAIIF
Date   Source Headline
28th Mar 20247:00 amRNSExpansion of Treat It to Mental Health Treatments
27th Mar 20245:11 pmRNSHolding(s) in Company
25th Mar 20247:00 amRNSGermany Medical Cannabis Legislation Reform
18th Mar 20249:14 amRNSAgritec Update
15th Jan 20247:00 amRNSPartnership to launch a Walk-In Pain Clinic
14th Nov 20237:00 amRNSContract Extension With Major UK Retailer
2nd Nov 20237:00 amRNSPartnership with BRITISH CANNABISâ„¢
29th Sep 20237:00 amRNSHalf-Year Results
31st Aug 202311:13 amRNSTotal Voting Rights
11th Aug 202311:36 amRNSIssuance of New Ordinary Shares and TVR
26th Jul 20232:00 pmRNSAdmission and Total Voting Rights
24th Jul 20234:10 pmRNSIssuance of New Ordinary Shares and TVR
17th Jul 20237:00 amRNSSuccess for Kanabo Agritec with Contract Award
10th Jul 202311:19 amRNSIssue of New Ordinary Shares and TVR
30th Jun 20232:34 pmRNSResult of AGM
28th Jun 20237:00 amRNSIssue of New Ordinary Shares and TVR
23rd Jun 20237:00 amRNSGrant of Options
13th Jun 20232:39 pmRNSPublication of a Prospectus
8th Jun 20235:19 pmRNSNotice of Annual General Meeting
31st May 202311:30 amRNSTotal Voting Rights
26th May 202310:30 amRNSTotal Voting Rights
23rd May 202311:00 amRNSIssuance of New Ordinary Shares
16th May 20233:00 pmRNSUpdate: Amendments to Acquisition Agreement
16th May 20237:00 amRNSAmendments to Acquisition Agreement
15th May 20237:00 amRNSTotal Voting Rights
12th May 20237:00 amRNSTotal Voting Rights
10th May 20232:52 pmRNSResult of Broker Option
9th May 20237:00 amRNSAppointment of Ian Mattioli as Non-Executive Chair
9th May 20237:00 amRNSFundraise of £2.54 million and Broker Option
4th May 20234:45 pmRNSBoard Change
2nd May 20237:00 amRNSFull Year Results 2022
31st Mar 20232:40 pmRNSDirectorate Change
13th Mar 20237:00 amRNSTreat It Launch: Online Medicinal Cannabis Clinic
7th Mar 202312:15 pmRNSAppointment of Auditor
14th Feb 20234:40 pmRNSSecond Price Monitoring Extn
14th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20237:00 amRNSBusiness Update
2nd Feb 20239:05 amRNSSecond Price Monitoring Extn
2nd Feb 20239:00 amRNSPrice Monitoring Extension
30th Jan 202311:05 amRNSSecond Price Monitoring Extn
30th Jan 202311:00 amRNSPrice Monitoring Extension
27th Jan 202311:05 amRNSSecond Price Monitoring Extn
27th Jan 202311:00 amRNSPrice Monitoring Extension
25th Jan 20232:05 pmRNSSecond Price Monitoring Extn
25th Jan 20232:00 pmRNSPrice Monitoring Extension
25th Jan 202311:05 amRNSSecond Price Monitoring Extn
25th Jan 202311:00 amRNSPrice Monitoring Extension
17th Jan 20237:00 amRNSLaunch of new products
30th Dec 20227:00 amRNSBoard Changes
2nd Dec 20222:59 pmRNSResignation of Auditor

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.